Sunday, October 1, 2023
Clinical Advances in
Progressive fibrosing interstitial lung diseases (ILDs)—including idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and others—can be challenging to identify, treat, and effectively monitor in practice. However, diagnostic and treatment approaches are fast evolving, and best practice is changing. Experts in this curriculum will address how the latest data can be applied to practice to reduce the rates of morbidity and mortality for these highly burdensome conditions.
Supported by an independent educational grant from
Steering Committee Chair
Professor
University of Lyon
Hôpital Louis Pradel
Lyon, France
Professor
Department of Rheumatology
University
Hospital Zurich
Zurich, Switzerland
Rheumatologist
University Hospital of Oslo
Oslo, Norway
Thoracic Radiologist
NIHR Clinician Scientist
Imperial College London
London, United Kingdom
Director
Division of Respirology
Department of Medicine
McMaster University
Hamilton, Ontario, Canada
Department of Pulmonology
Hannover Medical School
Hannover, Germany
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Galapagos NV; Gilead Sciences, Inc.; Promedior; Roche
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; Roche
Steering Committee Member
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Accerleron Pharma; AnaMar; Bayer HealthCare; Blade Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; CSL Behring;ChemomAb; Ergonex; GlaxoSmithKline; Genmark Pharmaceuticals; Inventiva; Italfarmaco; iQvia; Mitsubishi Tanabe Pharma; Merck Sharp & Dohme Corp; Roche Holdings AG; Sanofi; UCB Pharma, Inc.
Served as a speaker or a member of a speakers bureau for: Actelion Pharmaceuticals, Ltd; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; iQone; Menarini; Mepha; Merck Sharpe & Dohme Corp; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche holdings AG
Received grants for clinical research from: Actelion Pharmaceuticals, Ltd; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Mitsubishi Tanabe Pharma
Steering Committee Member
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.
Served as a speaker or a member of a speakers bureau for: Actelion Pharmaceuticals, Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Fluidda; Glapagos; Roche Holdings AG; OSIC
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Galapagos; Roche Holdings AG; OSIC
Received grants for clinical research from: NIHR
Has disclosed the following relevant financial relationships
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Roche Holdings AG
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Prometic; Roche Holdings AG
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Denko; Nitto; Pliant; Roche Holdings AG
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiesi Pharmaceuticals, Inc.; Roche Holdings AG
